WS Investor
12 Nov 2026, 16:45
Bristol Myers Squibb Unifies Research and Development Under Cristian Massacesi
Bristol Myers Squibb (NYSE: BMY) announced plans to combine its research and development functions into a single end-to-end organization as part of an effort to accelerate pipeline execution and improve decision-making.
Effective January 1, 2027, Cristian Massacesi, currently executive vice president and chief medical officer, will lead the unified R&D organization. Chief Research Officer Robert Plenge will remain with the company in an advisory role through March 2027 to support the transition before leaving Bristol Myers Squibb.
The company said the new structure is designed to more closely connect scientific discovery and clinical development, reducing organizational boundaries between the two functions and allowing promising programs to move through the pipeline with greater speed and focus.
Chief Executive Christopher Boerner said the reorganization should improve collaboration across R&D, strengthen portfolio execution and help Bristol Myers Squibb integrate new technologies and capabilities more effectively.
The move comes as large pharmaceutical companies increasingly seek to shorten development timelines and improve productivity across research portfolios, particularly as competition intensifies in areas such as oncology, immunology and cardiovascular medicine.
Bristol Myers Squibb said the unified organization will bring together scientific and clinical teams from discovery through development under a single leadership structure.
The reorganization is primarily an operational and leadership change rather than a new pipeline announcement, but it could have longer-term strategic significance if the tighter structure improves development speed, resource allocation and the conversion of early-stage science into commercial medicines.
Bristol Myers Squibb (NYSE: BMY) announced plans to combine its research and development functions into a single end-to-end organization as part of an effort to accelerate pipeline execution and improve decision-making.
Effective January 1, 2027, Cristian Massacesi, currently executive vice president and chief medical officer, will lead the unified R&D organization. Chief Research Officer Robert Plenge will remain with the company in an advisory role through March 2027 to support the transition before leaving Bristol Myers Squibb.
The company said the new structure is designed to more closely connect scientific discovery and clinical development, reducing organizational boundaries between the two functions and allowing promising programs to move through the pipeline with greater speed and focus.
Chief Executive Christopher Boerner said the reorganization should improve collaboration across R&D, strengthen portfolio execution and help Bristol Myers Squibb integrate new technologies and capabilities more effectively.
The move comes as large pharmaceutical companies increasingly seek to shorten development timelines and improve productivity across research portfolios, particularly as competition intensifies in areas such as oncology, immunology and cardiovascular medicine.
Bristol Myers Squibb said the unified organization will bring together scientific and clinical teams from discovery through development under a single leadership structure.
The reorganization is primarily an operational and leadership change rather than a new pipeline announcement, but it could have longer-term strategic significance if the tighter structure improves development speed, resource allocation and the conversion of early-stage science into commercial medicines.
